[Relevant pharmacologic data as a guide for use of beta-blockers in psychiatry].
In addition to their competitive blockade of the beta-receptors, beta-adrenergic-blocking drugs possess ancillary properties that may modulate their clinical effects. Among these properties, beta 1-selectivity, intrinsic sympathomimetic activity, lipid solubility, may affect pharmacokinetic and pharmacodynamic properties of beta-blockers. It could appear that lipid soluble drugs gain access to the Central Nervous System (CNS) more easily. But CNS effects of beta-blockers are probably modulated by other parameters. With those pharmacological data, the authors propose briefly a schematic use of main beta-blockers in psychiatry.
S.H.U. Hôpital Sainte-Anne, Paris.
A
A
Heim
J M
JM
Vanelle
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D001523:Mental Disorders / Q000097:blood* / Q000188:drug therapy / Q000523:psychology; D008657:Metabolic Clearance Rate / Q000502:physiology; D011485:Protein Binding / Q000502:physiology
D000319:Adrenergic beta-Antagonists
Les éléments pharmacologiques susceptibles de guider l'utilisation des bêta-bloquants en psychiatrie.